Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as ARO-MAPT-SC
ARO-MAPT · 1 trial · 2 indications
| Arm | Type | Description |
|---|---|---|
| ARO-MAPT-SC | EXPERIMENTAL | ARO-MAPT-SC injection |
| Placebo | PLACEBO_COMPARATOR | Sterile normal saline (0.9%) |
| Name | Type | Description |
|---|---|---|
| ARO-MAPT-SC | DRUG | • single or multiple doses of ARO-MAPT-SC by subcutaneous (SC) injection |
| Placebo | DRUG | • calculated volume to match active treatment by SC administration |
Inclusion Criteria (All Participants): * Body mass index between 18.0 and 35.0 kilograms (kg)/square meter (m\^2) at Screening * Not pregnant or breast-feeding * Able and willing to provide written informed consent prior to the performance of any study specific procedures * Participants of childbea...
Top 20 of 24 competitors
ARO-MAPT is an investigational small molecule being developed for Alzheimer's disease. It is currently in Phase 1 clinical development, studied in healthy participants and participants with early Alzheimer's disease, including early-onset Alzheimer's disease.
ARO-MAPT is being developed by Arrowhead Pharmaceuticals, Inc., a biopharmaceutical company traded on NASDAQ under the ticker symbol ARWR. The company is conducting a Phase 1 clinical trial of ARO-MAPT-SC, an alternative name for the drug.
ARO-MAPT is in Phase 1 clinical development. It is an investigational drug and has not been approved by regulatory authorities. The ongoing Phase 1 trial is recruiting participants in Canada and New Zealand.
ARO-MAPT is being studied in a Phase 1 clinical trial with the identifier NCT07221344. The trial is titled 'Study of ARO-MAPT-SC in Healthy Participants and Participants With Early Alzheimer's Disease' and is currently recruiting 112 participants.
Yes, ARO-MAPT is also known as ARO-MAPT-SC. The Phase 1 clinical trial NCT07221344 uses the name ARO-MAPT-SC to refer to the same investigational drug being developed by Arrowhead Pharmaceuticals.
Yes, the Phase 1 trial of ARO-MAPT is randomized, double-blind, and placebo-controlled. The study enrolls 112 participants, including healthy volunteers and individuals with early Alzheimer's disease, and is actively recruiting.